2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
2026 multisociety dyslipidemia guideline (Circulation 2026;153:e1154-e1276): endorses a lifetime-exposure model for ApoB-containing lipoproteins and recommends ApoB selectively to identify residual risk after LDL-C/non-HDL-C goals are met or when measures are discordant; Lp(a) measured at least once (>=125 nmol/L or >=50 mg/dL as a risk-enhancing factor).
Evidence
—
Not Rated
Sample
—
subjects
Duration
—
study period
Journal
Circulation
Jun 2026
Structured Methods
- Study Design
- Guideline
- Sample Size
- Not reported
- Study Duration
- Not reported
- Methodology
- Not reported
- Limitations
- Not reported
Citations & References
Unknown authors (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. https://doi.org/10.1161/CIR.0000000000001423
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
